TIGERMED - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

HANGZHOU TIGERMED CONSULTING CO., LTD.

Hangzhou Tiger Pharmaceutical Technology Co., Ltd. (a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 3347)

Overseas regulatory announcement

This announcement is made by Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. (the "Company") pursuant to a Hong Kong joint transaction made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities of Hong Kong Limited.

The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.

By order of the board of directors Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

Chairman Ye Xiaoping

Hong Kong, March 30, 2026

As at the date of this announcement, the executive directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Wen Zengyu Mr.; the independent non-executive directors are Mr. Liao Qiyu, Mr. Yuan Huagang and Ms. Liu Yuwen.

Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. 2025 Summary table of non-operating fund occupation and other related fund transactions Unit: 10,000 yuan

Capital occupied at the beginning of 2025 Total occupied capital in 2025 Accounting for listed companies Accounting profits from funds occupied in 2025 Annual repayment in 2025 Date of December 31, 2025 Occupation of non-operating funds Name of the party who occupies the funds Relationship between the occupier and the listed company Fund balance (including the new consolidated amount (excluding the reason for the occupation Nature of the occupation) Account Interest (if any) Amount incurred Ending current fund balance increase) interest) Controlling shareholders, actual controllers and Non-business occupation its affiliated companies Subtotal - - - - Former controlling shareholder and actual controller Non-business occupation and its affiliated companies Subtotal - - - -

Other related parties and affiliated enterprises Non-operating occupation

Subtotal Total - - - -

Capital occupied at the beginning of 2025 Total occupied capital in 2025 Accounting for listed companies Accounting profits from funds occupied in 2025 Annual repayment in 2025 Date of December 31, 2025 Other related capital transactions. Name of the capital counterparty. Related relationship between the counterparty and the listed company. Fund balance (including the new consolidated amount (excluding the new consolidated amount)). Reasons for the occupation. Nature of the occupation. Account Interest (if any) Amount incurred Ending current fund balance increase) interest) The actual controller Cao Xiaochun serves as director, and his children serve as directors. Zhiding Medical Technology Co., Ltd. Accounts receivable, contract assets 24.18 13.39 37.57 - Sale of goods/provision of services Operating transactions Executive Director and Manager Cao Xiaochun, the controlling shareholder, actual controller and actual controller of Yidisi Medical Technology (Jiaxing) Co., Ltd., serves as the chairman of the board. Accounts receivable, contract assets 364.29 820.93 392.14 793.08 Sale of goods/provision of services Operating transactions Its subsidiary Shenzhen Robo Medical Technology Co., Ltd. Actual controller Cao Xiaochun’s children serve as directors Accounts receivable, contract assets 79.52 55.84 133.37 1.99 Sale of goods/provision of services Operating transactions

Hangzhou Laimai Medical Information Technology Co., Ltd. Actual controller Cao Xiaochun’s children serve as directors Accounts receivable, contract assets 8.61 4.56 7.45 5.72 Sale of goods/provision of services Operating transactions Hangzhou Fanskai Technology Co., Ltd. The children of the actual controller Cao Xiaochun serve as its holding company Accounts receivable, contract assets 18.37 215.87 94.08 140.16 Sale of goods/provision of services Operating transactions

Capital occupied at the beginning of 2025 Total occupied capital in 2025 Accounting for listed companies Accounting profits from funds occupied in 2025 Annual repayment in 2025 Date of December 31, 2025 Occupation of non-operating funds Name of the party who occupies the funds Relationship between the occupier and the listed company Fund balance (including the new consolidated amount (excluding the reason for the occupation Nature of the occupation) Account Interest (if any) Amount incurred Ending current fund balance increase) interest) Supervisor of Hangzhou Fansiquan Technology Co., Ltd.

The spouse of the actual controller Cao Xiaochun serves as director (2025 Hangzhou Hezheng Pharmaceutical Co., Ltd. Accounts receivable, contract assets 402.03 493.39 328.35 567.07 Sale of goods/provision of services Operating transactions Resigned in November 2016) Hangzhou Taiyuan Pharmaceutical Innovation Research Institute Co., Ltd. Actual controller Cao Xiaochun serves as chairman Accounts receivable, contract assets 14.44 95.01 44.76 64.69 Sale of goods/provision of services Operating transactions Shanghai Youyin Pharmaceutical Biotechnology Co., Ltd. Actual controller Ye Xiaoping’s son-in-law serves as director Accounts receivable, contract assets 158.80 52.09 106.71 Sale of goods/provision of services Operating transactions

Chenghong Pharmaceutical (Weihai) Co., Ltd. Other related parties and its subsidiaries Accounts receivable, contract assets 8.20 8.20 Sale of goods/provision of services Operating transactions Hangzhou Zhilan Health Co., Ltd. Actual controller Cao Xiaochun serves as chairman Accounts receivable, contract assets 27.82 -19.64 8.18 Sale of goods/provision of services Operating transactions

Shanghai Baicheng Pharmaceutical Supply Chain Management Co., Ltd. Other related parties and its subsidiaries Accounts receivable, contract assets 7.50 7.50 - Sale of goods/provision of services Operating transactions

Actual controller Cao Xiaochun serves as Yidixi Pharmaceutical Co., Ltd. Shanghai Zhaohui Pharmaceutical Technology Co., Ltd. Accounts receivable, contract assets 51.38 29.50 44.49 36.39 Sale of goods/provision of services Operating transactions Director of Technology (Jiaxing) Co., Ltd. Hangzhou Hekang Pharmaceutical Co., Ltd. Actual controller Cao Xiaochun’s spouse serves as executive director Accounts receivable, contract assets 0.77 142.99 87.42 56.34 Sale of goods/provision of services Operating transactions Hangzhou Paqis Medical Technology Co., Ltd. Actual controller Cao Xiaochun and his spouse serve as executive directors Accounts receivable, contract assets 182.80 0.07 29.16 153.71 Sale of goods/provision of services Operating transactions

Beijing Jingwei Legend Pharmaceutical Technology Co., Ltd. Other related parties and its subsidiaries Accounts receivable, contract assets 4.50 - 4.50 Sale of goods/provision of services Operating transactions The actual controller Cao Xiaochun’s children serve as Hangzhou Laimai Beijing Laimai Medical Information Technology Co., Ltd. Accounts receivable, contract assets 0.64 - 0.64 Sale of goods/provision of services Operating transactions Director of Medical Information Technology Co., Ltd.

Suzhou Kunshi No. 1 Biotechnology Co., Ltd. Actual controller Ye Xiaoping’s son-in-law serves as director Accounts receivable, contract assets 26.84 25.29 1.55 Sale of goods/provision of services Operating transactions Actual controller Cao Xiaochun serves as Hangzhou Taiyuan Pharmaceutical Hangzhou Taiyuan Lizai Biotechnology Co., Ltd. Accounts receivable, contract assets 147.32 110.90 36.42 Sale of goods/provision of services Operating transactions Chairman of Innovation Research Institute Co., Ltd. The actual controller Ye Xiaoping serves as Dean Diagnostic Technology Hangzhou Dean Medical Laboratory Center Co., Ltd. Accounts receivable, contract assets 0.99 0.99 Sale of goods/provision of services Operating transactions Director of Group Co., Ltd. Hangzhou Taikun Equity Investment Fund Partnership (with other related parties and its subsidiaries Accounts receivable, contract assets 9,311.80 9,311.80 - Sale of goods/provision of services Operating transactions

Capital occupied at the beginning of 2025 Total occupied capital in 2025 Accounting for listed companies Accounting profits from funds occupied in 2025 Annual repayment in 2025 Date of December 31, 2025 Occupation of non-operating funds Name of the party who occupies the funds Relationship between the occupier and the listed company Fund balance (including the new consolidated amount (excluding the reason for the occupation Nature of the occupation) Account Interest (if any) Amount incurred Ending current fund balance increase) interest) limited partnership)

Actual controller Cao Xiaochun’s children serve as executive directors Hangzhou Moxun Technology Co., Ltd. Accounts receivable, contract assets 0.44 0.44 - Sale of goods/provision of services Operating transactions and general manager Tigerise, Inc. Other related parties and its subsidiaries Accounts receivable, contract assets 25.58 25.58 - Sale of goods/provision of services Operating transactions The actual controller Ye Xiaoping serves as Dean Diagnostic Technology Zhejiang Dian Deep Sea Supply Chain Co., Ltd. Accounts receivable, contract assets 1.13 1.13 - Sale of goods/provision of services Operating transactions Director of Group Co., Ltd. Subtotal 1,179.35 11,540.51 - 10,733.52 1,986.34

Subsidiaries of listed companies and their wholly-owned subsidiaries of Hong Kong Tigermed Pharmaceutical Technology Co., Ltd. Long-term receivables 35,919.68 775.68 35,144.00 Loans Non-operating transactions

Affiliated enterprises Hong Kong Tiger Health Technology Co., Ltd. Wholly-owned subsidiary Other receivables 718.84 15.96 702.88 Equity transfer non-operating transactions Subtotal 36,638.52 - - 791.64 35,846.88

PT TIGERMED MEDICAL Associates Other receivables 51.71 1.33 53.04 Loans Non-operating transactions INDONESIA Other related parties and its subsidiaries TIGERMED CO., LTD. Associates Other receivables 149.92 3.86 153.78 Loans Non-operating transactions Industry (THAILAND) Tigermed Vietnam Co., Limited Associates Other receivables 83.14 2.14 85.28 Loans Non-operating transactions

Yidixi Medical Technology (Jiaxing) Co., Ltd. Associates Other receivables - 39.42 - 39.42 Loans Non-operating transactions Subtotal 284.77 46.75 - - 331.52

Total 38,102.64 11,587.26 - 11,525.16 38,164.74 This table has been approved by the board of directors on March 30, 2026. Person in charge of the company (legal representative): Cao Xiaochun Person in charge of accounting work: Yang Chengcheng Person in charge of the accounting department: Chen Xiaocui